The potential value of cancer-testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy

被引：1

作者：

Lin, Lina ^{[1
,2
]}

Zou, Xiaoqiong ^{[1
]}

Nong, Weixia ^{[1
]}

Ge, Yingying ^{[1
]}

Li, Feng ^{[1
]}

Luo, Bin ^{[1
,3
]}

Zhang, Qingmei ^{[1
,3
]}

Xie, Xiaoxun ^{[1
,3
,4
]}

机构：

[1] Guangxi Med Univ, Sch Basic Med Sci, Dept Histol & Embryol, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China

[2] Guangxi Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Nanning, Guangxi, Peoples R China

[3] Guangxi Med Univ, Educ Dept Guangxi Zhuang Autonomous Reg, Key Lab Basic Res Reg Dis, Nanning, Guangxi, Peoples R China

[4] Guangxi Med Univ, Key Lab Early Prevent & Treatment Reg High Frequen, Minist Educ, Nanning, Guangxi, Peoples R China

来源：

IMMUNITY INFLAMMATION AND DISEASE | 2024年 / 12卷 / 06期

基金：

中国国家自然科学基金;

关键词：

CTA; ovarian cancer; tumor therapy; MESSENGER-RNA EXPRESSION; CANCER/TESTIS ANTIGENS; DNA METHYLATION; PROMOTER HYPOMETHYLATION; OY-TES-1; EXPRESSION; PROTEIN EXPRESSION; CELL-LINES; GERM-LINE; GENE; NY-ESO-1;

D O I：

10.1002/iid3.1284

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

BackgroundTumor immunotherapy has become an important adjuvant therapy after surgery, radiotherapy, and chemotherapy. In recent years, the role of tumor-associated antigen (TAA) in tumor immunotherapy has become increasingly prominent. Cancer-testis antigen (CTA) is a kind of TAA that is highly restricted in a variety of tumors and can induce an immune response.AimsThis review article aimed to evaluate the role of CTA on the progression of ovarian cancer, its diagnostic efficacy, and the potential for immunotherapy.MethodsWe analyzed publications and outlined a comprehensive of overview the regulatory mechanism, immunogenicity, clinical expression significance, tumorigenesis, and application prospects of CTA in ovarian cancer, with a particular focus on recent progress in CTA-based immunotherapy.ResultsThe expression of CTA affects the occurrence, development, and prognosis of ovarian cancer and is closely related to tumor immunity.ConclusionCTA can be used as a biomarker for the diagnosis and prognosis evaluation of ovarian cancer and is an ideal target for antitumor immunotherapy. These findings provide novel insights on CTA in the improvement of diagnosis and treatment for ovarian cancer. The successes, current challenges and future prospects were also discussed to portray its significant potential. Cancer-testis antigens (CTAs) exhibit carcinogenic potential and strong immunogenicity in ovarian cancer. This review outlines a comprehensive of overview the regulatory mechanism, immunogenicity, clinical expression significance, tumorigenesis, and application prospects of CTAs in ovarian cancer, all of which can provide novel insights in the improvement of diagnosis and treatment for ovarian cancer. image

引用

页数：17

共 114 条

[1] The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes [J].

Adair, Sara J. ;

Carr, Tiffany M. ;

Fink, Mitsu J. ;

Slingluff, Craig L., Jr. ;

Hogan, Kevin T. .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (01) :7-17

[2] Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules [J].

Adair, Sara J. ;

Hogan, Kevin T. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (04) :589-601

[3] Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder [J].

Afsharpad, Mandana ;

Nowroozi, Mohammad Reza ;

Mobasheri, Maryam Beigom ;

Ayati, Mohsen ;

Nekoohesh, Leila ;

Saffari, Mojtaba ;

Zendehdel, Kazem ;

Modarressi, Mohammad Hossein .

PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) :191-199

[4] The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma [J].

Agarwal, Sumit ;

Saini, Shikha ;

Parashar, Deepak ;

Verma, Archana ;

Sinha, Abhilasha ;

Jagadish, Nirmala ;

Batra, Aruna ;

Suri, Sushma ;

Gupta, Anju ;

Ansari, Abdul S. ;

Lohiya, Nirmal Kumar ;

Suri, Anil .

ONCOIMMUNOLOGY, 2013, 2 (05)

[5] Epithelial Ovarian Cancer: A Five Year Review [J].

Arnaoutoglou, Christos ;

Dampala, Kalliopi ;

Anthoulakis, Christos ;

Papanikolaou, Evangelos G. ;

Tentas, Ioannis ;

Dragoutsos, Georgios ;

Machairiotis, Nikolaos ;

Zarogoulidis, Paul ;

Ioannidis, Aristeidis ;

Matthaios, Dimitris ;

Perdikouri, Eleni I. ;

Giannakidis, Dimitrios ;

Sardeli, Chrysanthi ;

Petousis, Stamatios ;

Oikonomou, Panagoula ;

Nikolaou, Christina ;

Charalampidis, Charalampos ;

Sapalidis, Konstantinos .

MEDICINA-LITHUANIA, 2023, 59 (07)

[6] Expression of the POTE gene family in human ovarian cancer [J].

Barger, Carter J. ;

Zhang, Wa ;

Sharma, Ashok ;

Chee, Linda ;

James, Smitha R. ;

Kufel, Christina N. ;

Miller, Austin ;

Meza, Jane ;

Drapkin, Ronny ;

Odunsi, Kunle ;

Klinkebiel, David ;

Karpf, Adam R. .

SCIENTIFIC REPORTS, 2018, 8

[7] Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector [J].

Batchu, Ramesh B. ;

Gruzdyn, Oksana V. ;

Moreno-Bost, AMberly M. ;

Szmania, Susann ;

Jayandharan, Giridhararao ;

Srivastava, Arun ;

Kolli, Bala K. ;

Weaver, Donald W. ;

van Rhee, Frits ;

Gruber, Scott A. .

VACCINE, 2014, 32 (08) :938-943

[8] Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression [J].

Bertram, J ;

Palfner, K ;

Hiddemann, W ;

Kneba, M .

ANTI-CANCER DRUGS, 1998, 9 (04) :311-317

[9] NuMA Overexpression in Epithelial Ovarian Cancer [J].

Bruening-Richardson, Anke ;

Bond, Jaqueline ;

Alsiary, Rawiah ;

Richardson, Julie ;

Cairns, David A. ;

McCormac, Luci ;

Hutson, Richard ;

Burns, Philip A. ;

Wilkinson, Nafisa ;

Hall, Geoff D. ;

Morrison, Ewan E. ;

Bell, Sandra M. .

PLOS ONE, 2012, 7 (06)

[10] Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells [J].

Cameron, Brian J. ;

Gerry, Andrew B. ;

Dukes, Joseph ;

Harper, Jane V. ;

Kannan, Vivekanandan ;

Bianchi, Frayne C. ;

Grand, Francis ;

Brewer, Joanna E. ;

Gupta, Minnal ;

Plesa, Gabriela ;

Bossi, Giovanna ;

Vuidepot, Annelise ;

Powlesland, Alex S. ;

Legg, Alison ;

Adams, Katherine J. ;

Bennett, Alan D. ;

Pumphrey, Nicholas J. ;

Williams, Daniel D. ;

Binder-Scholl, Gwendolyn ;

Kulikovskaya, Irina ;

Levine, Bruce L. ;

Riley, James L. ;

Varela-Rohena, Angel ;

Stadtmauer, Edward A. ;

Rapoport, Aaron P. ;

Linette, Gerald P. ;

June, Carl H. ;

Hassan, Namir J. ;

Kalos, Michael ;

Jakobsen, Bent K. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (197)

← 1 2 3 4 5 6 7 8 9 10 →